These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 17006474)

  • 21. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 22. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 23. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 25. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 27. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 28. Devices and the food and drug administration.
    Phillips SJ; Phillips RS
    Artif Organs; 2005 May; 29(5):363-5. PubMed ID: 15854210
    [No Abstract]   [Full Text] [Related]  

  • 29. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 30. When a drug is withdrawn.
    Johnson LJ
    Med Econ; 2005 May; 82(10):68. PubMed ID: 15977763
    [No Abstract]   [Full Text] [Related]  

  • 31. Designing trials for testing prosthetic cardiac valves: a Food and Drug Administration perspective.
    Sapirstein W
    Am Heart J; 2001 May; 141(5):861-3. PubMed ID: 11320379
    [No Abstract]   [Full Text] [Related]  

  • 32. Rotavirus immunisation in Africa: a perspective re-visited.
    Steele D
    Afr J Health Sci; 2002; 9(3-4):113-6. PubMed ID: 17298153
    [No Abstract]   [Full Text] [Related]  

  • 33. The unfinished business of U.S. drug safety regulation.
    Evans BJ; Flockhart DA
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract]   [Full Text] [Related]  

  • 34. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug regulation 2056.
    Bezold C; Peck J
    Food Drug Law J; 2005; 60(2):127-36. PubMed ID: 16097091
    [No Abstract]   [Full Text] [Related]  

  • 36. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-review deadlines and safety problems.
    Nardinelli C; Lanthier M; Temple R
    N Engl J Med; 2008 Jul; 359(1):95-6; author reply 96-8. PubMed ID: 18596282
    [No Abstract]   [Full Text] [Related]  

  • 38. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
    Cotter J; Wooltorton E
    CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921
    [No Abstract]   [Full Text] [Related]  

  • 39. Avoiding the regulatory capture of the Food and Drug Administration.
    Egilman DS; Presler AH; Valentin CS
    Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.